ACME UNITED CORP (ACU) Form 8-K — Oct 27, 2026
Acme United (NYSE American: ACU) reported Q3 2026 net sales of $58.0 million, up 18% from $49.1 million a year ago, with comparable growth of 10% excluding the My Medic acquisition. Net income jumped 80% to $3.4 million, or $0.80 per diluted share, versus $0.46 last year. Gross margin expanded to 45.3% from 39.1%, boosted by roughly 690 basis points from a $4.0 million IEEPA tariff refund recognized in the quarter, partially offset by about 310 basis points of DMT facility closure costs. Nine-month sales rose 16% to $173.0 million with diluted EPS of $2.29.
Key figures
- Eps
- 0.8
- Revenue
- 58013000
- Net Income
- 3435000
- Revenue Yoy
- 18%
- Total Assets
- 207859000
- Cash Position
- 7944000
- Dividends paid
- $2.4 million
- Gross margin q3
- 45.3%
- Q3 2025 revenue
- 49063000
- Nine month revenue
- 173030000
- Q3 2025 net income
- 1903000
- Bank debt less cash
- $29.7 million vs $23.1 million prior year
- Q3 2025 eps diluted
- 0.46
- Tariff refund total
- $6.0 million (IEEPA), $4.0 million recognized in Q3
- Dmt closure costs q3
- $1.8 million
- Nine month net income
- 9469000
- Nine month eps diluted
- 2.29
- Nine month revenue yoy
- 16%
- Expected dmt savings 2027
- >$1.0 million annually
- My medic acquisition cost
- $14.5 million paid in twelve months ($18.6 million purchase price less $4.1 million holdbacks)
- Gross margin q3 prior year
- 39.1%
- Comparable growth ex my medic
- 10%
- Free cash flow trailing twelve months
- $13.8 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.